FDA Grants Accelerated Approval to Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory CLL, SLL

CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) approved for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously administered at least two lines of therapy.

Source link
#FDA #Grants #Accelerated #Approval #Bristol #Myers #Squibbs #Breyanzi #Relapsed #Refractory #CLL #SLL